<DOC>
	<DOCNO>NCT02226965</DOCNO>
	<brief_summary>This study sponsor Sierra Oncology , Inc. formerly ProNAi Therapeutics , Inc . It multi-center , nonrandomized , open label , phase II investigation PNT2258 characterize anti-tumor activity collect safety data patient relapsed refractory ( r/r ) diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>PNT2258 Treatment Patients With r/r DLBCL ( Wolverine )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically confirm diffuse large Bcell lymphoma refractory prior therapy relapse prior therapy . FDG PETCT ( disease ) positive baseline scan measurable disease . The patient must receive prior therapy include : CD20targeted therapy ( example , rituximab ) , Alkylating agent ( example , cyclophosphomide ) , Steroid , unless patient steroid intolerant Exposure least 1 2 ( 3 ) prior systemic cytotoxic chemotherapeutic regimen . Note : Only subject eligible highdose chemotherapy autologous stem cell transplant ( HDASCT ) , refuse HDASCT , eligible exposure 1 prior cytotoxic chemotherapeutic regimen . ECOG performance status 01 . The patient must stable baseline CTCAE grade ≤ 2 regard acute chronic toxicity associate prior therapy , discontinue prior anticancer therapy ≥ 14 day prior C1D1 ; mitomycinC least 6 week prior C1D1 ; SCT ≥ 2 month prior C1D1 . Note : Palliative steroid control diseaserelated symptom allow maintenance hormone therapy allow . Adequate organ function include : Hematologic : ANC ≥ 0.5 x 10^9/L . platelet ≥ 50 x 10^9/L . Hepatic : Total Bilirubin ≤ 2 x ULN ( patient Gilbert 's syndrome must total bilirubin ≤ 3 x ULN ) serum transaminase level ≤ 2.5 x ULN . In case know liver metastasis ( i.e. , radiological biopsy document ) , serum transaminase level must ≤ 5 x ULN . Renal : Serum creatinine ≤ 2 x ULN , creatinine clearance ≥ 60 mL/min/1.73 m2 subject serum creatinine level 2 x ULN . Willingness : 1 . ) undergo pretreatment biopsy obtain adequate tissue analysis ( e.g. , core needle , excisional incisional tumor biopsy ) 2 . ) provide archive tumor ( e.g. , FFPE block ) analysis . Eligibility highdose chemotherapy ( HDT ) stem cell transplant ( SCT ) . Note : Subjects progress ≥ 2 month HDT/SCT eligible Concurrent malignancy require treatment . Primary mediastinal ( thymic ) large Bcell lymphoma Symptomatic CNS leptomeningeal involvement lymphoma . Concurrent clinically significant illness , medical condition , surgical history , physical finding , electrocardiogram laboratory finding , opinion investigator , could adversely affect safety patient impair assessment study result . Signs symptoms heart failure characterize great NYHA Class II significant cardiac abnormality . Pregnant breastfeeding . Prior exposure PNT2258 . Life expectancy le 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PNT2258</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Diffuse Large B-cell Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
</DOC>